Dorsey & Whitney Trust CO LLC Sells 1,329 Shares of Vericel Co. (NASDAQ:VCEL)

Dorsey & Whitney Trust CO LLC lowered its stake in Vericel Co. (NASDAQ:VCEL) by 12.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 9,270 shares of the biotechnology company’s stock after selling 1,329 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Vericel were worth $482,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System boosted its holdings in Vericel by 19.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,199 shares of the biotechnology company’s stock valued at $843,000 after acquiring an additional 2,600 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Vericel by 10.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock valued at $53,149,000 after acquiring an additional 100,797 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in Vericel by 0.8% in the first quarter. William Blair Investment Management LLC now owns 841,677 shares of the biotechnology company’s stock valued at $43,784,000 after acquiring an additional 6,792 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Vericel by 8.3% during the 1st quarter. ProShare Advisors LLC now owns 12,985 shares of the biotechnology company’s stock valued at $675,000 after buying an additional 995 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Vericel by 49.4% during the 1st quarter. Sei Investments Co. now owns 49,340 shares of the biotechnology company’s stock valued at $2,567,000 after buying an additional 16,312 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, May 9th. TD Cowen assumed coverage on shares of Vericel in a report on Thursday, June 20th. They set a “buy” rating and a $55.00 target price on the stock. BTIG Research dropped their target price on shares of Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a report on Monday. StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Truist Financial boosted their target price on shares of Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Vericel has an average rating of “Moderate Buy” and an average target price of $51.33.

Vericel Trading Down 2.2 %

NASDAQ:VCEL traded down $1.12 during mid-day trading on Friday, reaching $50.11. The company’s stock had a trading volume of 364,584 shares, compared to its average volume of 472,600. Vericel Co. has a 12-month low of $30.18 and a 12-month high of $53.14. The firm’s fifty day moving average price is $46.83 and its two-hundred day moving average price is $45.79. The stock has a market cap of $2.44 billion, a P/E ratio of -5,005.99 and a beta of 1.70.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The firm had revenue of $51.28 million during the quarter, compared to analyst estimates of $49.07 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. Analysts predict that Vericel Co. will post 0.11 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sean C. Flynn sold 6,772 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $45.02, for a total transaction of $304,875.44. Following the completion of the sale, the insider now owns 487 shares of the company’s stock, valued at approximately $21,924.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $44.12, for a total transaction of $772,100.00. Following the completion of the transaction, the chief executive officer now directly owns 220,752 shares in the company, valued at approximately $9,739,578.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sean C. Flynn sold 6,772 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the transaction, the insider now owns 487 shares of the company’s stock, valued at $21,924.74. The disclosure for this sale can be found here. Insiders sold 63,791 shares of company stock valued at $3,101,269 in the last quarter. 5.20% of the stock is currently owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.